Chapter 35: Antidepressants

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement, not replace, the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

You know, usually when we talk about a medical diagnosis, there's this expectation of precision like engineering or something.

Absolutely, like a broken bone.

Right, you break your arm, the x -ray shows that jagged white line, and the doctor just points and says, well, there it is.

It's very binary, broken or not broken.

It's clean, it's visible, and frankly, I mean, it's comforting.

Yeah, but then you step into the world of neurodevelopment, trauma,

and psychiatric pharmacology, and suddenly that x -ray machine is just useless.

We're looking at a diagnostic landscape that is incredibly murky.

It is the absolute definition of diagnostic muddy waters, and that lack of a simple visible metric makes treating it pharmacologically feel like, well, a massive puzzle.

Which is exactly why we are plunging into this deep dive today, specifically tailored for you, the nursing student who is gearing up for pharmacology exams and clinical rotations.

Our mission today is to take the dense, often overwhelming drug data from Chapter 35 on antidepressants and translate it into clear cause and effect concepts.

Because the goal is that when you are standing at the Pyxis machine pulling medications or educating a newly diagnosed patient, you aren't just reciting a textbook.

Exactly.

You actually need to understand the underlying molecular mechanics of what is happening and why.

And this isn't just an academic exercise.

I mean, more than 300 million people worldwide suffer from major depression.

300 million, wow.

Yeah, it is the second most common psychiatric disorder globally, right behind anxiety, and yet, it is massively underdiagnosed.

So the concepts we are unpacking today, they're foundational for safe clinical practice.

So let's start with the baseline of what we're actually treating.

Because people use the word depressed casually all the time.

Like I'm depressed, my team lost, or I'm depressed about the rain.

Right, but clinical major depression is an entirely different beast from everyday grief or sadness.

Grief is an appropriate proportional reaction to a major life stressor.

Right, it makes sense.

Major depression, though, is a systemic illness.

For clinical diagnosis, you are looking for specific symptoms,

depressed mood, loss of pleasure in usual activities, insomnia or hypersomnia, significant weight changes.

Those are very physical, too.

Pervasive feelings of worthlessness, yes.

And crucially, these symptoms must be present most of the day, nearly every day, for at least two weeks.

Two weeks straight.

Yeah, it's that unyielding persistence that crosses the line into a major depressive episode.

Okay, so what is physically going wrong in the brain?

I've always heard this chemical imbalance theory.

Is depression really just low brain juice?

Like your cank of serotonin is just running near empty?

Well, the scientific term for that light brain juice idea is the monoamine deficiency hypothesis.

It asserts that depression is caused by functional deficiency of monoamine neurotransmitters, specifically norepinephrine, serotonin, or both.

Now, is it that simple?

No.

Because the brain is never simple.

The neurochemistry is vastly more complex than just a simple fluid deficiency.

But as a conceptual framework for understanding how our current primary drugs work, it is incredibly useful.

Okay, so it gives us a good working model.

Right.

Most of our medications are designed to increase the availability of those specific transmitters in the synaptic cleft.

That brings up a massive question for me, though.

If a patient has a headache, they take ibuprofen and 20 minutes later they feel better.

If depression is just a lack of neurotransmitters and these drugs immediately boost those transmitters, why can't a patient just take an antidepressant PRN?

Like just pop a pill on a particularly bad Tuesday and feel better by lunch.

That's a great question.

Because the relief of depressive symptoms doesn't actually come from that initial immediate boost in neurotransmitters.

Right, really?

Yeah, that is a fundamental rule of antidepressants.

The time course of response is extremely delayed.

An initial response takes one to three weeks to develop, and the maximal therapeutic response might not be seen for up to 12 weeks.

12 weeks.

So what is the brain doing during all those weeks?

It's essentially remodeling itself.

The prolonged exposure to increased neurotransmitters eventually triggers slow adaptive cellular changes in the brain.

The receptors themselves change in sensitivity and density.

That completely flips how I thought about it.

The drug is just the catalyst.

The brain rebuilding its own hardware is the actual cure.

You nailed it.

And that explains why adherence is such a struggle for patients.

I mean, they take a pill, they get side effects on day one, and they feel zero psychological relief.

So they just quit?

Which is why patient education is arguably your most powerful tool here as a nurse.

You have to prepare them for that delay.

And speaking of side effects, one of the most fascinating aspects of psychiatric nursing is how we can actually use side effects as a therapeutic tool.

Oh, I love that.

Turning a negative into a feature.

Exactly.

Since all the major antidepressant classes are roughly equal in their overall efficacy, you choose a drug by matching its side effect profile to the patient's specific symptoms.

So if a patient has severe fatigue along with their depression,

you wouldn't give them something that makes them sleepy.

No, you'd choose a stimulating drug like phylloxetine.

Conversely, if they are pacing the halls with insomnia and agitation, well, you choose a drug with heavy sedating properties like merdazapine.

That makes total sense.

If they have comorbid chronic pain, you might look at deloxetine, you're treating the whole clinical picture.

Exactly.

We have to talk about the black box warning, though, because it seems entirely counterintuitive to me.

You give a patient a drug to cure their depression,

and the primary safety alert is an increased risk for suicidal thoughts and behavior.

Yeah, it is a terrifying paradox.

This risk is most acute during the early phase of treatment, particularly for children, adolescents, and adults under 25.

Is that tied to that delayed response time we just talked about?

Yes, it is.

Think about the timeline.

Severe depression often robs patients of all their energy.

I mean, they might have suicidal ideation, but lack the physical and mental activation to formulate and actually carry out a plan.

Right, they're just too exhausted.

But as the drug begins to work, what often returns first?

Their energy and motivation.

Oh, wow.

So their physical energy returns weeks before their mood actually lifts.

Exactly.

They're still deeply depressed, but now they have the energy to act on it.

It's a very vulnerable window.

The nursing implications here are critical.

You are monitoring daily for clinical decline.

So sudden anxiety, severe agitation, panic attacks, new hostility.

And for inpatients, I imagine observation during medication administration has to be rigorous.

Extremely.

You can't just hand them a paper cup of pills and walk away.

You have to watch closely and often check their mouths to ensure they don't cheek the medication.

Shake it.

Like hiding it.

Yeah, hiding it to hoard multiple doses for an overdose later.

That is a chilling but vital clinical reality to keep at the forefront of your mind.

So let's get into the actual drug classes.

Let's do it.

The front line of defense, the most commonly prescribed medications are the selective serotonin reuptake inhibitors, or SSRIs, and the serotonin or pinephrine reuptake inhibitors, SNRIs.

Let's look at the SSRI prototype first fluoxetine, which is widely known as Prozac.

To understand fluoxetine, picture the synapse, the gap between two nerve cells.

Normally, the first cell releases serotonin into that gap to send a mood regulating signal to the second cell.

Okay, I'm picturing it.

Once the signal is sent, a reuptake pump on the first cell basically vacuums the serotonin back up to be recycled.

So if I'm thinking of this like a club, it's like a bouncer blocking the exit door.

The SSRI physically blocks that reuptake pump.

That's a great analogy.

The serotonin gets trapped in the synaptic space, forced to keep interacting with receptors.

But based on what we said earlier, it's the fact that the party gets so loud that the brain eventually notices and starts changing its own receptor structures.

That is a perfect synthesis of the short -term action and the long -term adaptation.

But because you are trapping serotonin everywhere in the body, not just in the mood centers of the brain, you get systemic side effects.

The adverse effects list for SSRIs is pretty significant.

Nausea, insomnia,

and one that I imagine leads to huge non -compliance issues, sexual dysfunction.

Oh, absolutely.

The text indicates it affects up to 70 % of men and women taking these drugs.

Impotence, delayed orgasm, completely flatlining libido.

It is incredibly common, and patients rarely volunteer this information because of embarrassment.

As a nurse, you have to be proactive here.

Right, you have to bring it up.

You must educate patients that this is a known physiological side effect of the medication.

It's not a personal failing.

You want them to know that so they don't just quietly abandon their treatment.

You also see significant weight gain with long -term treatment.

But the most immediate danger seems to be serotonin syndrome.

If we're blocking that reuptake pump, I imagine the serotonin levels can accidentally reach toxic levels.

Yes, serotonin syndrome is a medical emergency.

It usually begins 2 to 72 hours after starting treatment.

What does it look like?

The excessive serotonergic transmission causes a massive overstimulation of the central and peripheral nervous systems.

You see altered mental status, so agitation, severe confusion, hallucinations paired with hyperreflexia, excessive sweating, tremors, and a high fever.

And left untreated.

It can be fatal.

I would assume that risk skyrockets if you mix an SSRI with another drug that also boosts serotonin.

Which is an absolute contraindication.

You never combine SSRIs with MAOIs, for example.

And because fluoxetine has an incredibly long half -life, meaning it stays active in the body for a very long time,

if you are switching a patient from fluoxetine to an MAOI, you need a total washout period of at least 5 weeks.

You literally have to wait over a month for the SSRI to clear out before starting the new drug to avoid serotonin syndrome.

Wow.

Okay, I noticed another risk that caught me off guard.

GI bleeding.

Serotonin is primarily known as a brain chemical.

How does an SSRI cause a patient's stomach to bleed?

That's a brilliant question.

Platelets, the cells responsible for clotting blood, actually require serotonin to aggregate and form a plug when you have a bleed.

Oh, interesting.

But platelets cannot synthesize serotonin themselves.

They have to actively absorb it from the blood plasma using their own reuptake pumps.

Oh, and the SSRI is systemic.

Like it's not just blocking reuptake in the brain, it's blocking the reuptake pumps on the platelets too.

Exactly.

The platelets are starved of serotonin so they can't clot effectively.

This dramatically increases the risk for gastrointestinal bleeding, especially if the patient is concurrently taking NSAIDs like ibuprofen or anticoagulants like warfarin.

That mechanism completely bridges the gap between a seemingly random side effect and logical physiology.

Yeah, it all connects.

What about pregnant patients?

If a patient takes an SSRI while pregnant, what happens to the infant?

If used late in pregnancy, the newborn is suddenly cut off from the drug at birth, leading to neonatal abstinence syndrome, or NAS.

What are the symptoms of that?

The baby experiences withdrawal symptoms, abnormal high -pitched crying, significant tremors, and respiratory distress.

There is also a severe risk for persistent pulmonary hypertension of the newborn, PPHN, which severely compromises the infant's ability to oxygenate their blood.

And for mothers who are breastfeeding.

Well, not all SSRIs are created equal here.

Fluoxetine reaches high concentrations in breast milk and should be avoided.

Sirtraline, on the other hand, another SSRI, has been shown to be exceptionally safe for breastfeeding mothers.

That highlights why we have so many different SSRIs.

Things like citalopram, zitalopram, sirkaline, they're all roughly equal in curing depression, but their half -lives and specific safety profiles dictate which one you choose.

Exactly.

So what happens if an SSRI just isn't cutting it?

We move to the SNRIs.

The prototype here is venlafaxine.

Right.

SNRIs, serotonin, and norepinephrine reuptake inhibitors, you are blocking two different reuptake pumps now.

Two bouncers at two different doors.

But because we are adding norepinephrine into the mix, which is a key player in our sympathetic nervous system,

you know, our fight or flight response, the side effects must shift.

They do.

You still see the serotonin -related side effects like nausea and sexual dysfunction, but venlafaxine specifically introduces a risk of dose -related diastolic hypertension.

The excess norepinephrine constricts blood vessels.

So a key nursing intervention there is aggressive blood pressure monitoring.

You can't just assume an antidepressant only affects mood.

Exactly.

And I imagine the withdrawal from an SNRI is intense.

It is severe.

Abrupt discontinuation leads to a massive withdrawal syndrome.

Intense anxiety tremors tachycardia.

Patients feel physically ill.

It absolutely must be tapered slowly over two to four weeks.

Okay, so SSRIs and SNRIs are the safest,

most targeted options we have.

But what happens when a patient is entirely resistant to them?

Their depression just won't budge.

Then we have to bring in the heavier, older pharmacology.

The tricyclic antidepressants, or TCAs, and the monamine oxidase inhibitors, MAOIs.

Why are these considered second -line drugs?

Because while they are highly effective, their side effect profiles are brutal, and their safety margins are incredibly narrow.

Let's look at TCAs first.

The mechanism of action is technically similar to SNRIs.

They block the reuptake of norepinephrine and serotonin, but chemically they are very similar to phenothiazine antipsychotics.

I was reading the list of adverse effects for TCAs, and honestly it looks like a nightmare.

Profound sedation, orthostatic hypotension, dry mouth, blurred vision, urinary retention.

Are these drugs just indiscriminately hitting every receptor in the body?

That is exactly what they are doing.

We call them clumsy drugs.

In addition to targeting serotonin and norepinephrine, they directly bind to and block other unrelated receptors.

So they're just making a mess.

Kind of, yeah.

They block histamine receptors, which completely knocks the patient out, causing profound sedation.

They block alpha -1 adrenergic receptors on blood vessels.

Which means the blood vessels can't constrict properly.

So when the patient stands up, gravity pulls the blood down, the vessels fail to tighten, and their blood pressure bottoms out.

Right.

That explains the orthostatic hypotension perfectly.

It does.

And finally, they block muscarinic cholinergic receptors, causing classic anticholinergic effects, the dry mouth, the urinary retention, the severe constipation.

But the anticholinergic and alpha -blocking effects aren't even the most dangerous part.

It's the toxicity.

I saw that the lethal dose of a TCA is only eight times the average therapeutic dose.

That is an incredibly narrow therapeutic index.

How does it actually kill a patient in an overdose?

Severe cardiac toxicity.

The excessive blockade in the cardiac tissue disrupts electrical conduction, leading to fatal dysrhythmias.

So connecting the clinical dots, here we are treating severely depressed patients who carry a known risk of suicide, and we are handing them a bottle of pills.

Where just eight days' worth could kill them.

It's a massive liability.

That is why the critical nursing implication is that acutely depressed, suicidal patients should only ever be given a one -week supply of their TCA at a time.

Oh, that makes total sense.

And because of that cardio toxicity, every patient needs a baseline EKG before they even swallow their first dose.

Okay, let's pivot to the other older class, the MAOIs.

The prototypes here are drugs like phenylzine.

The mechanism here is totally different from the reuptake blockers.

Yes.

MAO, or monamine oxidase, is an enzyme present in nerve terminals.

Think of it as a cellular garbage disposal.

Okay, a garbage disposal.

Its sole job is to inactivate and destroy monamine neurotransmitters, norepinephrine, serotonin and dopamine after they have been used.

So if SSRIs block the exits to keep the neurotransmitters in the room,

MAOIs completely shut down the recycling plant.

Exactly.

By inhibiting that MAO enzyme, you stop the destruction of these neurotransmitters so they naturally accumulate and intensify transmission.

Precisely.

But here is the catch that makes MAOIs so notoriously difficult to manage.

MAO isn't just floating around in the brain.

It is highly concentrated in the liver and the intestinal wall.

Why is it in the gut?

To protect us from our food, there is a naturally occurring dietary substance called tiramine found in many foods.

Tiramine strongly promotes the release of norepinephrine.

Under normal circumstances, you eat tiramine, the MAO in your gut and liver destroys it instantly and you are fine.

But if a patient is taking an oral MAOI, that intestinal and hepatic MAO is inhibited, the garbage disposal is turned off everywhere.

Yes.

So that dietary tiramine passes directly into the systemic circulation completely intact.

It travels to the peripheral sympathetic nerve terminals, which are already heavily loaded with norepinephrine because of the MAOI, and triggers a massive explosive release of that norepinephrine into the bloodstream.

Which clamps down every blood vessel in the body, leading to a tiramine hypertensive crisis,

tachycardia, a blinding headache, a massive blood pressure spike that can rapidly lead to stroke and death.

It is a profound medical emergency, and the only way to prevent it is strict dietary restriction.

I was reading the list of tiramine -rich forbidden foods, and it's basically an Italian charcuterie board.

Pretty much.

Anything fermented, smoked or aged is completely off limits.

Aged cheeses, cured meats like salami and pepperoni, smoked fish, certain craft beers and wines.

You can't even eat avocados or figs if they're overripe.

The dietary non -compliance risk is huge, which is why MAOIs are rarely a first choice.

However, pharmacology has given us a very clever workaround, transdermal saligiline.

A patch.

How does a patch solve a dietary problem?

Because the medication is absorbed directly through the skin into the systemic blood supply, it completely bypasses the gastrointestinal tract.

At lower doses, like the 6mg patch, the drug level is high enough to inhibit MAO in the brain, but low enough that it doesn't inhibit the MAO in the gut and liver.

That is brilliant.

The gut's garbage disposal keeps running, destroying the tiramine in the food, while the brain's garbage disposal shuts down to treat the depression.

No strict dietary restrictions needed at that low dose.

It is a massive quality of life improvement for patients who need an MAOI.

Okay, let's look at a totally different scenario.

Let's say you have a patient who refuses to take an SSRI because they experienced severe sexual dysfunction, where they cannot tolerate the weight gain.

What do we do?

We look at the atypicals.

Drugs that just don't fit the standard bowl.

The prime example here is bupropion.

Structurally, bupropion is very similar to an amphetamine.

It has mild stimulant actions and acts as an appetite suppressant, so patients actually lose weight.

And uniquely among antidepressants, it does not cause sexual dysfunction.

In fact, it often enhances libido.

Okay, hold on.

It treats depression, you lose weight, and your sex drive goes up.

Why isn't this the holy grail?

Why isn't every single patient on bupropion?

Because of that amphetamine -like structure, it causes significant central nervous system stimulation and that excess electrical activity lowers the brain's seizure threshold.

Seizures are the side effect of greatest concern here.

The risk spikes sharply at doses above 450 milligrams a day.

So you have to rigorously screen your patients.

If they have a history of head trauma or an eating disorder like anorexia or bulimia, which already mess with electrolyte balances and seizure thresholds, bupropion is a massive risk.

Exactly.

Another atypical is mirtazapine.

It works by increasing the release of serotonin and norepinephrine, but crucially, it is a powerful blocker of histamine receptors.

And we know from the TCAs that blocking histamine equals profound sedation and weight gain.

So if a patient is losing weight rapidly due to severe depression and pacing the halls at 3 a .m., mirtazapine side effects suddenly become the exact therapeutic effects you want.

It's all about matching the puzzle pieces.

But what if the depression is entirely resistant to all of these oral medications?

We enter the realm of isketamine.

Which is administered as a nasal spray, right?

Yes.

Isketamine is fascinating because it doesn't primarily target monoamines.

It is an NMDA receptor antagonist working on the glutamate system.

It is literally a chemical mirror image of the anesthetic ketamine.

If it's related to ketamine, the side effects must be intensely disorienting.

They are.

It causes profound sedation and dissociation, a psychological feeling of being disconnected from your own body in reality.

That sounds intense.

Very.

Because of the abuse potential and these intense psychological effects, isketamine is a schedule 3 drug locked behind a very strict REMS program.

That's a risk evaluation and mitigation strategy.

What does that mean for the nurse, practically?

It means the patient cannot be given a prescription to take home.

They must come to a certified clinic, administer the nasal spray under direct supervision, and you must monitor them clinically for at least two hours post -dose.

Two hours.

Just to make sure they're okay?

Yes, to ensure they are medically and psychologically stable before they can leave.

It really emphasizes how powerful these compounds are.

Which brings us to the final frontier of our deep -dive non -conventionals and highly specific clinical scenarios.

Let's talk about the over -the -counter world first, St.

John's Wort.

Patients view it as natural, so they assume it's harmless.

And that assumption is incredibly dangerous.

St.

John's Wort is a nightmare for pharmacological interactions.

It strongly induces P450 enzymes in the liver.

Think of the P450 enzymes as the liver's drug -clearing incinerator.

St.

John's Wort basically throws gasoline on that incinerator.

Precisely.

It accelerates the metabolism of many other critical life -saving drugs, destroying them before they can work, rendering them entirely ineffective.

Furthermore, St.

John's Wort actively increases serotonergic transmission.

Yeah, so if a patient secretly takes it alongside their prescribed SSRI, they are drastically increasing their risk for lethal serotonin syndrome.

You must always aggressively ask about herbal supplements during your nursing assessments.

I also saw a really interesting note in the text about psilocybin, the active compound in magic mushrooms.

This represents the cutting edge of psychiatric research.

The FDA has actually granted psilocybin a breakthrough therapy designation for severe depression.

It acts as a direct agonist of the 5 -HT2A serotonin receptor.

So it bypasses the whole waiting period.

Exactly.

Unlike SSRIs that require weeks to force the brain to adapt, psilocybin works rapidly by directly mimicking serotonin at the receptor level.

Trials are showing rapid, profound reversals of treatment -resistant depression.

From the cutting edge to a very specific, highly vulnerable clinical population peripartum depression.

The text draws a very hard line between the transient baby blues and true PPD.

And as a nurse, distinguishing the two is critical.

The baby blues are common, affecting up to 80 % of women.

It involves mild tearfulness and anxiety that usually resolves on its own within 10 days of delivery.

Right.

True peripartum depression is a major depressive episode that begins either during pregnancy or within the first few months postpartum.

It affects roughly one in eight first -time mothers.

It is paralyzing.

It impairs the mother's ability to bond with or care for the infant.

And it does not resolve without intervention.

We talked earlier about using SSRIs like sertraline for breastfeeding mothers.

But there is a newer drug specifically engineered for PPD called Brexanolone.

Brexanolone is remarkable.

It is the first drug approved exclusively for moderate to severe PPD.

But its administration is uniquely intense.

It modulates GABA receptors, essentially resetting the brain's inhibitory pathways.

But it requires a continuous intravenous infusion over 60 straight hours.

60 hours on an IV just for depression.

And it also falls under a strict REMS program.

Why?

Because massively increasing GABA, which is the brain's primary calming neurotransmitter, can cause a sudden loss of consciousness and severe apnea.

Patients receiving this 60 -hour infusion must be continuously monitored with continuous pulse oximetry to ensure they haven't stopped breathing.

That is a serious commitment to monitoring.

It is.

But the payoff is that clinical trials show a massive, rapid, and sustained reduction in depressive symptoms in a matter of days rather than months.

That is incredible.

The amount of ground we have covered today is just staggering.

From the baseline monamine hypothesis, through the synaptic bouncers and recycling plants of our reuptake inhibitors and MAOIs, all the way to the atypicals and 60 -hour 5E infusions.

If we pull all the way back and look at the trajectory of everything we've discussed, I want to leave you with a final thought to mull over.

For over half a century, our entire pharmacological approach has been shackled to the monamine deficiency hypothesis.

Right, the serotonin and norepinephrine.

Exactly.

We tweak serotonin, we tweak norepinephrine, and we wait weeks for the brain to slowly adapt.

But look at what is happening right now.

With the rapid success of ischidamine working on glutamate, brexanolone manipulating GABA, and psilocybin directly agonizing receptors in a matter of hours, are we standing on the precipice of a total paradigm shift?

Are we about to completely rewrite how we understand and treat the fundamental neurochemistry of depression?

It definitely feels like the tectonic plates of psychiatric medicine are shifting.

And as a future nurse, you are going to be standing right on the front lines of that shift.

You're going to need to know exactly when you can trust the standard protocol and when you are wading into the muddy waters of complex brain chemistry.

On behalf of the Deep Dive team, thank you so much for exploring this with us and keep asking the right questions.